Global RSV Diagnostics Market Projected to Grow at a CAGR of 9.4% According to a newly published market research report by 24LifeSciences, global RSV diagnostics market was valued at USD 795 million in 2025 and is projected to grow from USD 870 million in 2026 to reach USD 1,470 million by 2034, growing at a compound annual growth rate (CAGR) of 9.4% during the forecast period. Respiratory Syncytial Virus (RSV) diagnostics encompass the critical tests and methods used to detect the presence of the virus, a leading cause of severe lower respiratory tract infections worldwide. Primarily affecting vulnerable populations such as infants, young children, and older adults, these diagnostics include rapid antigen detection tests (RADTs), molecular assays like PCR, and viral culture techniques, each offering different levels of speed and specificity for clinical decision-making in both hospital and outpatient settings. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9340/rsv-diagnostics-market

Lichen Nitidus Treatment Market to Reach USD 153 million by 2034 According to a newly published market research report by 24LifeSciences, global lichen nitidus treatment market was valued at USD 107 million in 2025 and is projected to grow from USD 112.6 million in 2026 to reach USD 153 million by 2034, growing at a compound annual growth rate (CAGR) of 5.3% during the forecast period. Lichen nitidus is a chronic, inflammatory skin condition characterized by tiny, 1–2 mm, discrete, shiny, flat-topped papules most commonly affecting children and young adults. While often asymptomatic, it can cause significant cosmetic concerns and pruritus in some patients, driving demand for effective management strategies. Its pathogenesis remains incompletely understood, but it is considered a T-cell mediated inflammatory disorder often appearing as a "miniature lichen planus" variant. The absence of approved therapies specifically for this condition means treatment relies heavily on off-label use of corticosteroids, retinoids, and immunomodulators to manage symptoms and improve skin appearance. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9515/lichen-nitidus-treatment-market

How Personalized Medicine Is Shaping the Future of Retinoblastoma Treatment According to a newly published market research report by 24LifeSciences, global retinoblastoma treatment market value is at USD 82.1 million in 2026 and is projected to reach USD 112.7 million by 2032, growing at a compound annual growth rate (CAGR) of 5.9% during the forecast period. Retinoblastoma is a rare pediatric eye cancer that primarily affects children under five years old, originating in the retina. This malignancy presents significant treatment challenges due to its occurrence in very young patients and the critical need to preserve vision whenever possible. The treatment landscape is highly specialized, incorporating chemotherapy, radiation therapy, laser therapy, cryotherapy, and surgical interventions. Recent advances in superselective intra-arterial chemotherapy and intravitreal chemotherapy have revolutionized care by delivering targeted treatment directly to the tumor site, maximizing efficacy while minimizing systemic side effects. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9358/retinoblastoma-treatment-market